archive

July 27, 2012 Researchers say that expanding anti-retroviral treatment to all HIV-positive people in couples with one partner who isn't infected is cost-effective even in developing countries with limited budgets.

Summary

July 23, 2012 The leading international AIDS conference returns to the U.S. after a 22-year hiatus. A lot has happened in the years since the conference was last here. Treatments have turned a disease with a near-certain death sentence into a disease that people can live with for decades. And there is evidence that the epidemic could be greatly slowed or even stopped.

Summary

July 19, 2012 Each year hundreds of thousands South Africans become infected with HIV, so it might seem that a drug to slow transmission would be welcome. But there's concern about unintended consequences if Truvada is used widely for prevention.

Summary

July 17, 2012 Some Brazilian researchers say Truvada should only be given to very specific groups at risk of getting HIV, like young, gay men. Others are concerned that a drug that blocks the transmission of HIV could be a set-back for safe sex campaigns and might actually encourage unsafe sexual behavior.

Transcript

On All Things ConsideredPlaylist

July 17, 2012 Truvada, the first HIV prevention pill, costs about $13,000 a year, and it's not clear whether insurers will pay for it. And while taking a daily pill sounds simple, the new prevention strategy involves some complicated issues.

Transcript

On Morning EditionPlaylist

July 16, 2012 The drug was approved for people who test negative for HIV infection. It's supposed to be used in combination with safe-sex practices, such as using a condom, to reduce infection risk.

Transcript

On All Things ConsideredPlaylist

November 24, 2010 In the first hour of Talk of the Nation, the political junkie, and the promise of an HIV pill.  In our second hour, a Mickey Mantle biography that shows the hero and the human being, and traveling while fat.

Summary